Get the Stockscreener App
114.31
2.07%
2.32
After Hours:
114.20
-0.11
-0.10%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $114.31, with a volume of 11.19M.
It is up +2.07% in the last 24 hours and up +17.60% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$111.99
Open:
$112.15
24h Volume:
11.19M
Relative Volume:
1.70
Market Cap:
$142.43B
Revenue:
$28.75B
Net Income/Loss:
$480.00M
P/E Ratio:
308.95
EPS:
0.37
Net Cash Flow:
$10.83B
1W Performance:
+3.97%
1M Performance:
+17.60%
6M Performance:
+44.70%
1Y Performance:
+58.54%
1-Day Range:
$111.81
$114.77
1-Week Range:
$108.40
$114.77
52-Week Range:
$62.07
$114.77
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
114.31 | 142.43B | 28.75B | 480.00M | 10.83B | 0.37 |
|
LLY
Lilly Eli Co
|
920.63 | 874.97B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
90.65 | 402.40B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
209.03 | 369.01B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
165.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
92.25 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79 - Yahoo Finance
Altrius Capital Management Inc Has $4.38 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wakefield Asset Management LLLP Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
SVB Wealth LLC Invests $7.15 Million in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Mutual of America Capital Management LLC Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Los Angeles Capital Management LLC Has $44.59 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Richard Bernstein Advisors LLC Sells 5,653 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Crestwood Advisors Group LLC - MarketBeat
4,626 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by JFG Wealth Management LLC - MarketBeat
National Pension Service Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
GILEAD SCIENCES, INC. SEC 10-K Report - TradingView
Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating - Marketscreener.com
Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy? - Nasdaq
QRG Capital Management Inc. Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Oppenheimer Asset Management Inc. Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Car T Cell Therapy Market Projected To Witness Substantial Growth, 2025-2032: Legend Biotech, Gilead Sciences - EIN News
Impax Asset Management Group plc Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Roche, Gilead top patient groups' rankings of pharma ESG practices - FiercePharma
Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer - ACCESS Newswire
Gilead Sciences stock hits 52-week high at $112.11 - Investing.com
Gilead Sciences stock hits 52-week high at $112.11 By Investing.com - Investing.com Canada
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Nasdaq
NewEdge Wealth LLC Has $37.39 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Pinnacle Financial Partners Inc Takes $265,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Red Biotechnology Market Growth and Future Scope 2025-2032 | Amgen Inc., Gilead Sciences, Inc., Biogen - openPR
Why Gilead Sciences Remains A Buy After A 40% Rally - Seeking Alpha
A Better, Patient-Centered Health Care System is Possible Through New Partnership Between Patient Insight Institute, Michigan Oncology Quality Consortium & Gilead - PR Newswire
Non-Small Cell Lung Cancer Market Set for Significant Growth Across the 7MM During the Study Period (2025-2034) Due to the Rising Novel Therapeutic Options | DelveInsight - GlobeNewswire Inc.
The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant - Yahoo Finance
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors - Yahoo Finance
South Dakota Investment Council Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic - MSN
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s Trodelvy® in Advanced Breast Cancer - Business Wire
Gilead’s lenacapavir applications for HIV gain EMA validation - Yahoo Finance
ING Groep NV Sells 133,302 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
GILD: 3 Pharmaceutical Stocks With Blockbuster Drug Potential - StockNews.com
Gilead Sciences Unusual Options Activity - Benzinga
Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU - Marketscreener.com
Gilead’s lenacapavir could revolutionize HIV prevention - PharmaLive
Gilead announces European Medicines Agency validation for lenacapavir - TipRanks
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention - Yahoo Finance
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC - PMLiVE
Harnessing innovation to accelerate progress and end the HIV epidemic by 2030 - Financial Times
Analyst predicts Gilead’s lenacapavir could revolutionize HIV prevention - The Pharma Letter
Gene Therapy Market Top Companies Study- Novartis Ag, Biogen - openPR
Optimistic Buy Rating for Gilead Sciences Driven by Anticipated FDA Approval and Strategic Market Positioning - TipRanks
Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks - Insider Monkey
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus.com
Notable analyst calls this week: Airbnb, Gilead and Snowflake stocks among top picks (MRK:NYSE) - Seeking Alpha
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise - MarketBeat
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP - Clinical Trials Arena
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Feb 18 '25 |
Sale |
104.09 |
2,500 |
260,225 |
169,061 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):